166 related articles for article (PubMed ID: 18206292)
1. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?
Margulis V; Wood CG
Eur Urol; 2008 Sep; 54(3):489-92. PubMed ID: 18206292
[No Abstract] [Full Text] [Related]
2. [Treatment of locally advanced renal tumors].
Sánchez Zalabardo D; Millán Serrano JA; De Pablo Cárdenas A; Cuesta Alcalá JA
Actas Urol Esp; 2010 Feb; 34(2):134-41. PubMed ID: 20403277
[TBL] [Abstract][Full Text] [Related]
3. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
4. [Targeted therapies: sequential and combined treatments].
Gross-Goupil M; Escudier B
Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Rini BI
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
[TBL] [Abstract][Full Text] [Related]
6. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
7. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
9. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
11. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Kruck S; Kuczyk MA; Gakis G; Kramer MW; Stenzl A; Merseburger AS
Rev Recent Clin Trials; 2008 Sep; 3(3):212-6. PubMed ID: 18782079
[TBL] [Abstract][Full Text] [Related]
13. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
14. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
15. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
16. Current treatment considerations in metastatic renal cell carcinoma.
Haddad H; Rini BI
Curr Treat Options Oncol; 2012 Jun; 13(2):212-29. PubMed ID: 22410708
[TBL] [Abstract][Full Text] [Related]
17. Targeted drugs for metastatic renal cell carcinoma.
Motzer RJ; Basch E
Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
[No Abstract] [Full Text] [Related]
18. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
19. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.
Ito T; Kutikov A
Nat Rev Urol; 2015 Feb; 12(2):69-70. PubMed ID: 25600094
[No Abstract] [Full Text] [Related]
20. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]